多西他赛联合吡柔比星化疗治疗乳腺癌对患者肿瘤标志物水平的改善探讨

Study on the improvement of tumor marker levels in patients with breast cancer treated with cetaxel combined with pirarubicin chemotherapy

目的探讨多西他赛联合吡柔比星化疗治疗乳腺癌对患者肿瘤标志物水平的改善情况。方法选取2019年1月至2019年12月于济宁市梁山县人民医院就诊的72例乳腺癌患者,按照掷硬币分组法进行分组,对照组(字面)36例实施紫杉醇联合吡柔比星治疗,观察组(花面)36例予以多西他赛联合吡柔比星治疗。比较两组患者的肿瘤标志物水平、不良反应发生情况、疾病控制情况、1年生存率及复发率。结果化疗后,观察组患者的癌胚抗原、CA125、CA153水平以及1年复发率均低于对照组,疾病控制率高于对照组,差异具有显著性(P<0.05);两组患者的药物不良反应发生率与1年生存率比较差异无显著性(P>0.05)。结论乳腺癌患者采用多西他赛联合吡柔比星化疗治疗具有较为理想的效果,可改善肿瘤标志物水平,且不增加药物不良反应发生率及复发情况的发生。

Objective To study the improvement of tumor marker levels in patients with breast cancer treated with docetaxel combined with pirarubicin chemotherapy.Method A total of 72 breast cancer patients who were treated in Liangshan County People's Hospital in Jining City from January 2019 to December 2019 were included in this study.They were divided into groups according to the coin toss method.The control group(typeface)of 36 patients received paclitaxel combined with pirarubicin.36 cases in the observation group(flower face)were treated with docetaxel combined with pirarubicin.The tumor marker levels,toxic and side effects,disease control,1-year survival rate and recurrence rate were compared between the two groups.Result After chemotherapy,the levels of CEA,CA125,CA153 and the 1-year recurrence rate in the observation group were lower than those in the control group,and the disease control rate was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference between the incidence rate and the 1-year survival rate(P>0.05).Conclusion Cetaxel combined with pirarubicin chemotherapy for breast cancer patients has an ideal effect,which can improve the level of tumor markers,and does not increase the incidence of adverse drug reactions and recurrence.